Trilaciclib

Drug Profile

Trilaciclib

Alternative Names: G1T 28; G1T28-1

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator G1 Therapeutics
  • Class Antineoplastics; Chemoprotectants; Cyclohexanes; Piperazines; Pyrazines; Pyridines; Pyrimidines; Pyrimidinones; Pyrroles; Radioprotectives; Small molecules; Spiro compounds
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Small cell lung cancer
  • Phase I Cancer; Myelosuppression

Most Recent Events

  • 04 Aug 2017 Phase-II clinical trials in Small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (IV)
  • 02 Jun 2017 Efficacy and adverse events data from a phase-I/II clinical trials in Small-cell lung cancer (Combination therapy, First-line therapy) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 24 May 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top